Structural Formula (01c5574c 1056 49c6 Af20 E950db3f4139 01)
Crixivan
Product Images NDC 21695-366
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Crixivan (NDC 21695-366). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Indinavir Protocol Figure 1 (01c5574c 1056 49c6 Af20 E950db3f4139 02)
This appears to be a chart or graph displaying the proportion of patients on different treatment regimens (IDV+ZDV+L or ZDV+L) over a study period of 40 weeks. The numbers in the chart may represent the number of patients on each treatment at each time point. However, without further context or a clearer image, it is difficult to provide more specific information.*
Cd4 Cell Counts Figure 2 (Study ACTG 320)
This appears to be a table comparing the effectiveness of two different combinations of medications for HIV treatment. The first combination includes Indinavir, Zidovudine, and Lamivudine, while the second combination only includes Zidovudine and Lamivudine. The table displays results by study week and IDV+ZDV+L had higher numbers for each week.*
Indinavir Protocol 028 Figure 3 (01c5574c 1056 49c6 Af20 E950db3f4139 04)
This is a chart showing the proportion of patients on different treatment regimens (1DV + ZDV, Indinavir + Zidovudine, and Indinavir alone or Zidovudine alone) over a 48-week study period. The chart also includes the number of patients (N) at each study week for each regimen.*
Indinavir Protocol 028 Figure 4 (01c5574c 1056 49c6 Af20 E950db3f4139 05)
This appears to be a table with no clear meaning as there are no column or row headings. It is likely a dataset from a scientific study analyzing the effects of a combination of Indinavir and Zidovudine on patients. Without additional information or context, it is not possible to provide a detailed description.*
Indinavir Protocol 035 Figure 5 (01c5574c 1056 49c6 Af20 E950db3f4139 06)
This appears to be a table showing the RNA change (Log10 copies/mL) for different drug combinations of Indinavir, Zidovudine, and Lamivudine at different study weeks. There are three different drug combinations tested (Indinavir+Zidovudine+Lamivudine, Indinavir, and Zidovudine+Lamivudine), with 30-33 participants in each group. The study lasted for 24 weeks.*
Indinavir Protocol 035 Figure 6 (01c5574c 1056 49c6 Af20 E950db3f4139 07)
Indinavir Protocol 035 Figure 7 (01c5574c 1056 49c6 Af20 E950db3f4139 08)
This document appears to be a chart or table presenting data regarding three different treatments. The treatments are Indinavir + Zidovudine + Lamivudine, Indinavir, and Zidovudine + Lamivudine. The top row appears to show a dosage in grams. The left-hand column shows a cell count change, and the rows below it contain numbers that seem to correspond with individual weeks of the study. There are also ID numbers for each treatment. In some cases, the box is populated with a number, while in others, it only contains an "N". Without more context, it is difficult to draw any further conclusions from this data.*
Crixivan 400mg (01c5574c 1056 49c6 Af20 E950db3f4139 09)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
